drugset
Drugs / ABBV-3373
last change Apr 2023 re-read 2 minutes ago

ABBV-3373

targets NR3C1, TNF via inhibition

Developed for
rheumatoid arthritis
Investigated by
AbbVie

Trials 1 · a red edge is where a trial was stopped

today NCT03823391 · Ph 2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03823391 Mar 2019 → Apr 2020 rheumatoid arthritis AbbVie Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2020-06-10 AbbVie Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis abbvie.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as ABBV-3373 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03823391 ↗
Action Inhibit “anti-tumor necrosis factor (anti-TNF) monoclonal antibody” PMID 36512671 ↗ Apr 2023
Target NR3C1 “Glucocorticoid receptor modulator” CHEMBL4297572 ↗
Target TNF “the anti-tumor necrosis factor (anti-TNF) monoclonal antibody adalimumab linked to a glucocorticoid receptor modulator (GRM)” PMID 36512671 ↗ Apr 2023